Nicholas Investment Partners, LP Neurocrine Biosciences Inc Transaction History

Nicholas Investment Partners, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	BUY	$130.86 - $143.19 $383,550 - $419,689	2,931 New	2,931 $403,000
Q2 2020 Aug 12, 2020	SELL	$85.09 - $130.36 $2.35 Million - $3.61 Million	-27,668 Closed	0 $0
Q1 2020 May 13, 2020	SELL	$75.11 - $113.76 $130,841 - $198,169	-1,742 Reduced 5.92%	27,668 $2.4 Million
Q4 2019 Feb 13, 2020	SELL	$86.8 - $118.57 $913,222 - $1.25 Million	-10,521 Reduced 26.35%	29,410 $3.16 Million
Q3 2019 Nov 13, 2019	BUY	$83.82 - $101.5 $497,974 - $603,011	5,941 Added 17.48%	39,931 $3.6 Million
Q2 2019 Aug 09, 2019	BUY	$72.24 - $91.27 $263,242 - $332,587	3,644 Added 12.01%	33,990 $2.87 Million
Q1 2019 May 15, 2019	BUY	$69.31 - $91.53 $492,586 - $650,503	7,107 Added 30.58%	30,346 $2.67 Million
Q4 2018 Feb 14, 2019	BUY	$68.32 - $124.36 $78,499 - $142,889	1,149 Added 5.2%	23,239 $1.66 Million
Q3 2018 Nov 14, 2018	SELL	$98.88 - $125.85 $119,743 - $152,404	-1,211 Reduced 5.2%	22,090 $2.72 Million
Q2 2018 Aug 14, 2018	BUY	$75.3 - $105.99 $174,168 - $245,154	2,313 Added 11.02%	23,301 $2.29 Million
Q1 2018 May 15, 2018	BUY	$75.88 - $92.43 $1.59 Million - $1.94 Million	20,988 New	20,988 $1.74 Million

627

94.3M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12.2B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Nicholas Investment Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Nicholas Investment Partners, LP with notifications on news.